» Authors » Octavio Aravena

Octavio Aravena

Explore the profile of Octavio Aravena including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 20
Citations 427
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Maggi J, Carrascal M, Soto L, Neira O, Cuellar M, Aravena O, et al.
Ann Rheum Dis . 2022 Apr; 81(8):1096-1105. PMID: 35459695
Objective: Rheumatoid arthritis (RA) immunopathogenesis revolves around the presentation of poorly characterised self-peptides by human leucocyte antigen (HLA)-class II molecules on the surface of antigen-presenting cells to autoreactive CD4 +T...
2.
Catalan D, Mansilla M, Ferrier A, Soto L, Oleinika K, Aguillon J, et al.
Front Immunol . 2021 May; 12:611795. PMID: 33995344
Regulatory B cells (Bregs) is a term that encompasses all B cells that act to suppress immune responses. Bregs contribute to the maintenance of tolerance, limiting ongoing immune responses and...
3.
Alhabbab R, Nova-Lamperti E, Aravena O, Burton H, Lechler R, Dorling A, et al.
Immunol Rev . 2019 Sep; 292(1):164-179. PMID: 31559645
The interest in regulatory B cells (Bregs) began in the 1970s with the evidence that B cells could downregulate the immune system by the production of "inhibitory" antibodies. Subsequently, a...
4.
Garcia-Gonzalez P, Maggi J, Schinnerling K, Sepulveda-Gutierrez A, Soto L, Neira O, et al.
Front Immunol . 2019 Jun; 10:1171. PMID: 31191540
The potential of tolerogenic dendritic cells (tolDCs) to shape immune responses and restore tolerance has turn them into a promising therapeutic tool for cellular therapies directed toward immune regulation in...
5.
Garcia-Gonzalez P, Schinnerling K, Sepulveda-Gutierrez A, Maggi J, Mehdi A, Nel H, et al.
Front Immunol . 2017 Nov; 8:1350. PMID: 29109727
There is growing interest in the use of tolerogenic dendritic cells (tolDCs) as a potential target for immunotherapy. However, the molecular bases that drive the differentiation of monocyte-derived DCs (moDCs)...
6.
Aravena O, Ferrier A, Menon M, Mauri C, Aguillon J, Soto L, et al.
Arthritis Res Ther . 2017 Jan; 19(1):8. PMID: 28103916
Background: Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by excessive production of extracellular matrix by fibroblasts on skin and internal organs. Although Th2 cells have been involved in...
7.
Soto L, Ferrier A, Aravena O, Fonseca E, Berendsen J, Biere A, et al.
Front Immunol . 2015 Oct; 6:496. PMID: 26483788
The activation threshold of B cells is tightly regulated by an array of inhibitory and activator receptors in such a way that disturbances in their expression can lead to the...
8.
Pena C, Garate D, Contreras-Levicoy J, Aravena O, Catalan D, Aguillon J
Clin Dev Immunol . 2013 Jul; 2013:296031. PMID: 23818913
Background. Pharmacologically modulated dendritic cells (DCs) have been shown to restore tolerance in type II collagen-(CII-) induced arthritis (CIA). We examined the effect of dexamethasone (DXM) administration as a preconditioning...
9.
Garate D, Rojas-Colonelli N, Pena C, Salazar L, Abello P, Pesce B, et al.
Arthritis Rheum . 2012 Sep; 65(1):120-9. PMID: 22972370
Objective: Dendritic cells (DCs) modulated with lipopolysaccharide (LPS) are able to reduce inflammation when therapeutically administered into mice with collagen-induced arthritis (CIA). The aim of this study was to uncover...
10.
Aravena O, Pesce B, Soto L, Orrego N, Sabugo F, Wurmann P, et al.
Immunobiology . 2011 Aug; 216(12):1256-63. PMID: 21840621
The aim of this work was to study the effect of anti-TNF treatment on CD4+ Th1, Th17 and regulatory T cells (Tregs), together with CD8+ T cells and NK cells...